meningococcal serogroup B vaccine (Bexsero, Trumenba, 4CMenB)
Jump to navigation
Jump to search
Indications
- prevention of infection with Neisseria meningitidis serogroup B
- persons at high-risk for infection with meningococcal serogroup B infection[3][8]
- persistent complement component deficiency
- anatomic or functional asplenia
- microbiologists routinely exposed to isolates of Neisseria meningitidis
- serogroup B meningococcal disease outbreak[5]
- persons at high-risk for infection with meningococcal serogroup B infection[3][8]
- ACIP gives weak recommendation for young people at their physician's discretion[6]
- patients ages 16-23 may be vaccinated, preferably at age 16-18
- insufficient evidence to recommend vaccinating all adolescents[7]
- FDA-approved for patients age 10-25 years[7]
Contraindications
Benefit/risk
- 82% with antibodies that kill 4 N meningitidis serogroup B strains after vaccination (vs 1% without vaccination)
- seems to prevent meningitis, but carriage of N meningitidis persists in vaccinated individuals[4]
Dosage
- 3 doses for Trumenba, 2 for Bexsero at least one month apart
- 2 doses of Trumenba for patients aged 16-23 years not at increased risk[10]
- may be given with other vaccines, but should be given at different location[10]
Adverse effects
Mechanism of action
- multicomponent vaccine
- ~2/3 of vaccinated college students show effective bactericidal activity against outbreak strain of serogroup B N meningitidis despite 2 antigens in common[8]
Notes
- 2 trials show immunologic response of bivalent meningococcal B vaccine, but do not show that the vaccine protects against clinical meningococcal infection[11]
More general terms
Additional terms
References
- ↑ FDA News Release. October 29, 2014 First vaccine approved by FDA to prevent serogroup B Meningococcal disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm420998.htm
- ↑ FDA News Release. January 23, 2015 FDA approves a second vaccine to prevent serogroup B meningococcal disease. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm431370.htm
- ↑ 3.0 3.1 Young K, Sofair A, Chavey WE ACIP Recommends Serogroup B Meningococcal Vaccines in High-Risk People. Physician's First Watch, Feb 27, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Pfizer News Release. Thursday, February 26, 2015 CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk. http://www.pfizer.com/news/press-release/press-release-detail/cdc_advisory_committee_on_immunization_practices_votes_to_recommend_serogroup_b_meningococcal_disease_vaccination_for_persons_at_increased_risk - ↑ 4.0 4.1 McNamara LA et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics 2015 May; 135:798 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25917990 <Internet> http://pediatrics.aappublications.org/content/135/5/798
- ↑ 5.0 5.1 Folaranmi T et al Use of Serogroup B Meningococcal Vaccines in Persons Aged >= 10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Weekly. June 12, 2015 / 64(22);608-612 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6422a3.htm
- ↑ 6.0 6.1 JWatch editors ACIP Offers Weak Recommendation for Serogroup B Meningococcal Vaccine for Younger People Physician's First Watch, June 26, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
- ↑ 7.0 7.1 7.2 7.3 MacNeil JR, Rubin L, Folaranmi T et al Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Weekly. October 23, 2015 / 64(41);1171-6 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6441a3.htm
- ↑ 8.0 8.1 8.2 Basta NE et al Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. N Engl J Med 2016; 375:220-228. July 21, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27468058 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1514866
Kim JH A Challenge in Vaccine Development - Neisseria meningitidis Serogroup B. N Engl J Med 2016; 375:275-278. July 21, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27468064 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1606015 - ↑ AAP Committee on Infectious Diseases. Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. Pediatrics 2016 Sep; 138:e20161890. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27573083
- ↑ 10.0 10.1 10.2 Patton ME, Stephens D, Moore K, MacNeil JR. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep 2017;66:509=513. https://www.cdc.gov/mmwr/volumes/66/wr/mm6619a6.htm
- ↑ 11.0 11.1 Ostergaard L et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med 2017 Dec 14; 377:2349 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29236639 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1614474
- ↑ Mbaeyi SA, Bozio CH, Duffy J et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69(No. RR-9):1-41. Sept 25, 2020 Not indexed in PubMed https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION BEXSERO (Meningococcal Group B Vaccine) suspension, for intramuscular injection https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF